Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

160.74USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$160.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
503,003
52-wk High
$192.15
52-wk Low
$123.73

Chart for

About

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas... (more)

Overall

Beta: 1.33
Market Cap(Mil.): $48,902.74
Shares Outstanding(Mil.): 303.96
Dividend: 0.89
Yield (%): 0.65

Financials

  SHPG.OQ Industry Sector
P/E (TTM): 26.50 30.61 33.50
EPS (TTM): 6.07 -- --
ROI: 3.09 13.57 13.17
ROE: 5.66 15.25 14.98

Japan's Takeda shares drop as investors fret over Shire pursuit

TOKYO Takeda Pharmaceutical Co Ltd shares lost almost 5 percent of their value on Friday as investors fretted over the size of any deal the Japanese firm would have to make to seal its record-breaking purchase of London-listed Shire PLC.

2:23am EDT

UPDATE 2-Japan's Takeda shares drop as investors fret over Shire pursuit

* Takeda likely needs to up bid's cash component -analysts (Recasts, adds analyst comments)

2:13am EDT

BRIEF-Allergan confirms does not intend to make Shire

* ALLERGAN NOW CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR SHIRE Source text for Eikon: Further company coverage: (Reporting by Maiya Keidan)

2:05am EDT

Shire rejects $63 billion Takeda bid as Allergan drops pursuit

NEW YORK/LONDON Rare disease drug maker Shire Plc said on Thursday it had rejected a $63 billion cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co Ltd , while Allergan Plc reversed course on pursuing a rival bid.

Apr 19 2018

PRESS DIGEST- British Business - April 20

April 20 The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

Apr 19 2018

Deals of the day-Mergers and acquisitions

April 19 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: ** Rare disease drug maker Shire Plc said it had rejected a $63 billion cash-and-stock acquisition offer by Japan's Takeda Pharmaceutical Co Ltd, while Allergan Plc reversed course on pursuing a rival bid. ** Austrian property group Immofinanz is putting its 26 percent stake in peer CA Immo on the block, it said, after a review of its strategic options.

Apr 19 2018

UPDATE 5-Shire rejects $63 bln Takeda bid as Allergan drops pursuit

* Shire takeover fights follows surge in drug sector M&A (Adds new Allergan statement)

Apr 19 2018

BRIEF-Allergan Does Not Intend To Make An Offer For Shire; Strategic Review Continues

* ALLERGAN DOES NOT INTEND TO MAKE AN OFFER FOR SHIRE PLC; STRATEGIC REVIEW CONTINUES

Apr 19 2018

UPDATE 1-Shire, commodity stocks lift FTSE to 10-week high

* Debenhams' outlook cut adds to retail gloom (Adds detail and quote, updates prices at close)

Apr 19 2018

BRIEF-Allergan Confirms It Is In Early Stages Of Considering Possible Offer For Shire

* ALLERGAN ISSUES STATEMENT REGARDING PRESS SPECULATION ON ITS STRATEGIC REVIEW

Apr 19 2018

Earnings vs. Estimates